Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks for your replies. Have a good evening and lets look forward to another good day tomorrow!!! igor88
I have a question for anyone who knows.. I sold my shares after the dividend date was completed and still got my divy. I recently bought a bunch of shares the other day @.003 Will I get a divy on these shares and will I continue to get yhe divy on the ones I no longer own??? Thanks igor88
.0047 X .0049 come on .005 LOL!!!
.0041 x .0046 now last trade at .0046 .005 would be nice close!!
It might be a good time to pick up some HGSI on this dip! igor88
GM all!!! HGSI $1.00 today!! Good luck to all. igor88
Good morning getthapaper. Did you get some HGSI when I mentioned it? Up big time today!!! GL!
HOLDING STRONG TODAY!!! IGOR88
Thanks obi, looks like gap filled and it moves higher!! Take care. igor88
GM OBI What does the chart of HGSI tell you? Thanks
HGSI .78 Looking good! igor88
Good morning getthapaper!! IMO HGSI gonna see 1.00 again this week. Check out the chart! Conference on Wednesday. Good luck to you.
HGSI .72 X .77 Gonna se .80+ today! John Hancock Growth Trust in for 102,857 shares as of Friday the 13th.
http://www.mffais.com/hgsi.html
Yes indeed! Holding steady here. Very bullish if you ask me. igor88
HGSI .72 x .74!!! I mentioned this one a couple days ago at .48 Looks like another good day for this one! igor88
.72 X .74 premarket! Looking like its gonna be another green day. igor88
HGSI holding onto gains very well. Should see a run into close and a gapper in A.M. Good luck to all! igor88
Moving back up again! Looking very bullish to me! igor88
HGSI is holding onto gains!! Lets se .75 today
WEEE!!! look at us go up!!!
HGSI .57 and climbing, shorts are covering. up .09
yes indeed. Seems to be holding here better than it did yesterday so far. Let's hope it continues. igor88
HGSI looks like bottom yesterday. Now at .55 igor88
Good morning Sharing. Sure hope so. Back to 1.00 would be nice!! igor88
HGSI up .05 to .53 X .54 Could run today!! igor88
Looking better today!! Lets hope it can hold onto gains today. igor88
HGSI is the last lupus trial drug standing gentec cancled their phase 3 lupus trial yesterday that alone should push HGSI higher today. igor88
Just sent an email to investor relations asking about the possibility of shorting and a buyback. Will let you know if I receive a reply! igor88
Biotech Human Genome's Plan B: Lupus Drug
03/11/09 - 11:30 AM EDT
, HGSI , GSK , LJPC , BMRN , DNA Adam Feuerstein
With shares of Human Genome Sciences(HGSI Quote - Cramer on HGSI - Stock Picks) at an all-time low, the company's next shot at a turnaround lies with a risky phase III study of a lupus drug due in July.
More on HGSI Human Genome's Albuferon Cures Nearly Half of CasesFour Must-See Charts of the DayBristol-Myers to Buy Rights to Hep C DrugBiotech Confab: First Look at Today's NewsBiotech Mailbag: Who Will Run FDA? Market Activity BioMarin Pharmaceuticals Inc| BMRN DOWNGenentech Inc| DNA UPGlaxoSmithKline PLC| GSK DOWNThe Bethesda, Md.-based biopharmaceutical firm released disappointing results from a phase III study of its hepatitis C drug Albuferon on Monday, which caused the stock price to fall 67% to 55 cents a share and remain near that level Wednesday.
Analysts who follow Human Genome Sciences say the setback with Albuferon raises the stakes for the company's other late-stage drug candidate, LymphoStat-B. Two phase III studies of LymphoStat-B in patients with systemic lupus erythematosus, or SLE, are under way, with data from the first study expected in July.
Human Genome Sciences is developing LymphoStat-B in partnership with GlaxoSmithKline(GSK Quote - Cramer on GSK - Stock Picks).
There are no approved drugs to treat SLE, or lupus, although steroids are commonly used to treat symptoms. Recently, a drug from La Jolla Pharmaceuticals(LJPC Quote - Cramer on LJPC - Stock Picks) and BioMarin Pharmaceuticals(BMRN Quote - Cramer on BMRN - Stock Picks) was a failure in a phase III study of lupus patients. Rituxan, an otherwise wildly successful cancer and autoimmune drug for Genentech(DNA Quote - Cramer on DNA - Stock Picks), also failed a phase III lupus study last year. A second Rituxan study in lupus is under way.
Lupus is a chronic disease in which the body's immune system attacks connective tissue, resulting in inflammation and tissue damage, often to the heart, joints, lungs and kidneys. Women are more often diagnosed with lupus than men, and the disease goes through periods where it flares up then goes into remission.
LymphoStat-B is a human monoclonal antibody designed to recognize and tamp down the biological activity of B-lymphocyte stimulator, or BLyS, a substance that was discovered by Human Genome Sciences.
Biotech Human Genome's Plan B: Lupus Drug
03/11/09 - 11:30 AM EDT
, HGSI , GSK , LJPC , BMRN , DNA Adam Feuerstein
With shares of Human Genome Sciences(HGSI Quote - Cramer on HGSI - Stock Picks) at an all-time low, the company's next shot at a turnaround lies with a risky phase III study of a lupus drug due in July.
More on HGSI Human Genome's Albuferon Cures Nearly Half of CasesFour Must-See Charts of the DayBristol-Myers to Buy Rights to Hep C DrugBiotech Confab: First Look at Today's NewsBiotech Mailbag: Who Will Run FDA? Market Activity BioMarin Pharmaceuticals Inc| BMRN DOWNGenentech Inc| DNA UPGlaxoSmithKline PLC| GSK DOWNThe Bethesda, Md.-based biopharmaceutical firm released disappointing results from a phase III study of its hepatitis C drug Albuferon on Monday, which caused the stock price to fall 67% to 55 cents a share and remain near that level Wednesday.
Analysts who follow Human Genome Sciences say the setback with Albuferon raises the stakes for the company's other late-stage drug candidate, LymphoStat-B. Two phase III studies of LymphoStat-B in patients with systemic lupus erythematosus, or SLE, are under way, with data from the first study expected in July.
Human Genome Sciences is developing LymphoStat-B in partnership with GlaxoSmithKline(GSK Quote - Cramer on GSK - Stock Picks).
There are no approved drugs to treat SLE, or lupus, although steroids are commonly used to treat symptoms. Recently, a drug from La Jolla Pharmaceuticals(LJPC Quote - Cramer on LJPC - Stock Picks) and BioMarin Pharmaceuticals(BMRN Quote - Cramer on BMRN - Stock Picks) was a failure in a phase III study of lupus patients. Rituxan, an otherwise wildly successful cancer and autoimmune drug for Genentech(DNA Quote - Cramer on DNA - Stock Picks), also failed a phase III lupus study last year. A second Rituxan study in lupus is under way.
Lupus is a chronic disease in which the body's immune system attacks connective tissue, resulting in inflammation and tissue damage, often to the heart, joints, lungs and kidneys. Women are more often diagnosed with lupus than men, and the disease goes through periods where it flares up then goes into remission.
LymphoStat-B is a human monoclonal antibody designed to recognize and tamp down the biological activity of B-lymphocyte stimulator, or BLyS, a substance that was discovered by Human Genome Sciences.
IMO good buy here at .50 Seems to be bouncing off that! igor88
HGSI bottoming out at 52 week low. Good buy here imo. igor88
HGSI .54 X .55 Looking good in premarket! igor88
HGSI .54 X .55 Looking good this AM! igor88
HGSI good buy here at .54 Should bounce back to .60 Take care all. igor88
I just tried an order through ameritrade. No go!
Me too!!! We could use a little good news for Christmas!!! Take care!!! Merry Christmas.
10:00 am your time
Are we ready for liftoff with this news!!!! igor88